BioCentury | Apr 6, 2019
Finance

Everybody up

...disease patients. Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) FDA rescinds breakthrough therapy designation for Tonix's Tonmya cyclobenzaprine...
BioCentury | Mar 14, 2019
Company News

Tonix's PTSD therapy loses breakthrough therapy designation

...FDA rescinded breakthrough therapy designation for Tonix's Tonmya cyclobenzaprine (Sublingual TNX-102) to treat military-related posttraumatic stress...
...Holding Corp. (NASDAQ:TNXP) said it would stop the HONOR trial after the sublingual formulation of cyclobenzaprine...
BioCentury | Aug 3, 2018
Clinical News

Tonix stops Phase III of PTSD candidate on lack of separation from placebo

...endpoint in the next pivotal trial of the candidate. Tonmya is a sublingual formulation of cyclobenzaprine...
...Neurology Molecular target: Serotonin (5-HT2A) receptor; Adrenergic receptor α 1 (ADRA1) Description: Sublingual formulation of cyclobenzaprine...
...sleep quality Status: Interim Phase III data Milestone: NA Elizabeth S. Eaton Tonmya (Sublingual TNX-102, TNX-102 SL, cyclobenzaprine) Tonix...
BioCentury | Jun 30, 2018
Finance

Eyes on launches

...N.V. (NASDAQ:MYL) Revefenacin (TD-4208) COPD PDUFA date 11/13/18 Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Tonmya sublingual cyclobenzaprine...
BioCentury | May 11, 2018
Financial News

Neurana closes $60M series A

...the compound led to cognitive impairment levels comparable to placebo and superior to active comparator cyclobenzaprine...
BioCentury | May 7, 2018
Financial News

Neurana closes $60M series A

...the compound led to cognitive impairment levels comparable to placebo and superior to active comparator cyclobenzaprine...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...Recurrent high-grade glioma Interim Ph III data 2H18 Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Tonmya sublingual cyclobenzaprine...
BioCentury | Apr 20, 2017
Clinical News

TNX-102 SL: Ph III HONOR started

...Molecular target: Serotonin (5-HT2A) receptor ; adrenergic receptor alpha 1 (ADRA1) Description: Sublingual formulation of cyclobenzaprine...
BioCentury | Jan 27, 2017
Clinical News

TNX-102 SL: Ph II AtEase data

...Adrenergic receptor alpha 1 (ADRA1) ; Histamine H1 receptor (HRH1) Description: Sublingual formulation of cyclobenzaprine...
BioCentury | Dec 21, 2016
Clinical News

TNX-102 SL regulatory update

...the company plans to start the Phase III HONOR trial of the sublingual formulation of cyclobenzaprine...
...to treat PTSD. Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), New York, N.Y. Product: TNX-102 SL, sublingual cyclobenzaprine...
...Neurology Alicia Parker TNX-102 SL Tonmya Tonix Pharmaceuticals Holding Corp. Adrenergic receptor alpha 1 (ADRA1) Histamine H1 receptor (HRH1) Serotonin (5-HT2A) receptor sublingual cyclobenzaprine...
Items per page:
1 - 10 of 51